Whole Blood Biospecimen Collection for Subjects With Fanconi Anemia
NCT ID: NCT05910853
Last Updated: 2024-04-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
4 participants
OBSERVATIONAL
2023-05-24
2024-03-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Skin and Blood Research Samples From Healthy Volunteers and Patients With Hematologic Diseases
NCT00840567
Long-Term Follow-up of Subjects With Fanconi Anaemia Subtype A Treated With ex Vivo Gene Therapy
NCT04437771
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
NCT03937817
Blood Sampling for Research Related to Sickle Cell Disease
NCT00542230
Establishing a Repository of Blood and DNA Samples From People With Sickle Cell Disease (Comprehensive Sickle Cell Centers Collaborative Genotype-Phenotype Database and Sample Repository)
NCT00528203
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Fanconi Anemia (Non-Specific Genotypes)
Cohort 1-Fanconi Anemia (Non-Specific Genotypes) (N=4):
Inclusion:
1. The participant is willing and able to provide written informed consent
2. The participant is willing and able to provide appropriate photo identification
3. Participants aged 18 to 85
4. Participants have been diagnosed with Fanconi Anemia complementation group A\*Inclusion preference (not required for enrollment into the study): 1)
Participants preferentially have one of the following genotypes:
c3788\_3790delTCT, c295 G to T, c3558-3559 insertion of G, or c1115\_1118delTTGG
Exclusion:
1. Participants who are pregnant or are nursing
2. Participants with a known history of HIV, hepatitis, or other infectious diseases
3. Participants who have taken an investigational product in the last 30 days Participants who have experienced excess blood loss, including blood donation, defined as 250 mL in the last month or 500 mL in the previous two months
Specimen Donation
Blood donation
Fanconi Anemia (c3788_3790delTCT)
Cohort 2 - Fanconi Anemia (c3788\_3790delTCT) (N=1):
Inclusion:
1. The participant is willing and able to provide written informed consent
2. The participant is willing and able to provide appropriate photo identification
3. Participants aged 18 to 85
4. Participants have been diagnosed with Fanconi Anemia complementation group A
5. 1 participant must be diagnosed with the following genotype: c3788\_3790delTCT
Exclusion:
1. Participants who are pregnant or are nursing
2. Participants with a known history of HIV, hepatitis, or other infectious diseases
3. Participants who have taken an investigational product in the last 30 days Participants who have experienced excess blood loss, including blood donation, defined as 250 mL in the last month or 500 mL in the previous two months
Specimen Donation
Blood donation
Fanconi Anemia (c295 G to T)
Cohort 3 - Fanconi Anemia (c295 G to T) (N=1):
Inclusion:
1. The participant is willing and able to provide written informed consent
2. The participant is willing and able to provide appropriate photo identification
3. Participants aged 18 to 85
4. Participants have been diagnosed with Fanconi Anemia complementation group A
5. 1 participant must be diagnosed with the following genotype: c295 G to T
Exclusion:
1. Participants who are pregnant or are nursing
2. Participants with a known history of HIV, hepatitis, or other infectious diseases
3. Participants who have taken an investigational product in the last 30 days Participants who have experienced excess blood loss, including blood donation, defined as 250 mL in the last month or 500 mL in the previous two months
Specimen Donation
Blood donation
Fanconi Anemia (c3558-3559 insertion of G)
Cohort 4 - Fanconi Anemia (c3558-3559 insertion of G) (N=1):
Inclusion:
1. The participant is willing and able to provide written informed consent
2. The participant is willing and able to provide appropriate photo identification
3. Participants aged 18 to 85
4. Participants have been diagnosed with Fanconi Anemia complementation group A
5. 1 participant must be diagnosed with the following genotype: c3558-3559 insertion of G
Exclusion:
1. Participants who are pregnant or are nursing
2. Participants with a known history of HIV, hepatitis, or other infectious diseases
3. Participants who have taken an investigational product in the last 30 days Participants who have experienced excess blood loss, including blood donation, defined as 250 mL in the last month or 500 mL in the previous two months
Specimen Donation
Blood donation
Fanconi Anemia (c1115_1118delTTGG)
Cohort 5 - Fanconi Anemia (c1115\_1118delTTGG) (N=1):
Inclusion:
1. The participant is willing and able to provide written informed consent
2. The participant is willing and able to provide appropriate photo identification
3. Participants aged 18 to 85
4. Participants have been diagnosed with Fanconi Anemia complementation group A
5. 1 participant must be diagnosed with the following genotype: c1115\_1118delTTGG
Exclusion:
1. Participants who are pregnant or are nursing
2. Participants with a known history of HIV, hepatitis, or other infectious diseases
3. Participants who have taken an investigational product in the last 30 days Participants who have experienced excess blood loss, including blood donation, defined as 250 mL in the last month or 500 mL in the previous two months
Specimen Donation
Blood donation
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Specimen Donation
Blood donation
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The participant is willing and able to provide appropriate photo identification
* Participants aged 18 to 85
* Participants have been diagnosed with Fanconi Anemia complementation group A
Exclusion Criteria
* Participants with a known history of HIV, hepatitis, or other infectious diseases Participants who have taken an investigational product in the last 30 days Participants who have experienced excess blood loss, including blood donation, defined as 250 mL in the last month or 500 mL in the previous two months
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sanguine Biosciences
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Andrew C Frisina, M.S.
Role: STUDY_CHAIR
Sanguine Biosciences
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sanguine Biosciences
Woburn, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SAN-09686
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.